Back to all studies
CompletedNCT01810783

Interventional, Flexible-dose Extension Study of Brexpiprazole in people with Schizophrenia

This study is completed in the United States, in Estonia, in Poland, .... It is testing brexpiprazole for schizophrenia.

SchizophreniaDrugFrom 18 Years to 65 Years

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Then choose your country and confirm availability with each study site.

In plain English

Key information made simple

What is this study testing?

This study is testing whether Brexpiprazole may be useful for adults experiencing schizophrenia.

What would participation involve?

Participants may receive Brexpiprazole, attend study visits with the research team. The registry lists locations in Estonia, in Poland, and in Romania.

Who is it mainly for?

This study appears to be mainly for adults with schizophrenia.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View official study record (opens in a new tab)
  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateJuly 2013
Recruitment status
Completed
Enrollment listed in the registry
210
Sponsor
H. Lundbeck A/S
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, Estonia, Poland, ...
Age range
From 18 Years to 65 Years
Official registry ID
NCT01810783
Official title
Interventional, Open-label, Flexible-dose Extension Study of Brexpiprazole in Patients With Schizophrenia

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: NCT01810783. We help you review the study, but cannot decide medical eligibility.

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

View official study record (opens in a new tab)

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

Estonia · 2 sites
  • EE002
    Pärnu
    Site status: Not listed — confirm with the team
  • EE001
    Tallinn
    Site status: Not listed — confirm with the team
Poland · 3 sites
  • PL002
    Choroszcz
    Site status: Not listed — confirm with the team
  • PL005
    Choroszcz
    Site status: Not listed — confirm with the team
  • PL004
    Gdansk
    Site status: Not listed — confirm with the team
Romania · 6 sites
  • RO004
    Brasov
    Site status: Not listed — confirm with the team
  • RO007
    Bucharest
    Site status: Not listed — confirm with the team
  • RO011
    Bucharest
    Site status: Not listed — confirm with the team
  • RO012
    Bucharest
    Site status: Not listed — confirm with the team
  • RO010
    Iași
    Site status: Not listed — confirm with the team
  • RO006
    Piteşti
    Site status: Not listed — confirm with the team
Russia · 7 sites
  • RU001
    Arkhangelsk
    Site status: Not listed — confirm with the team
  • RU008
    Moscow
    Site status: Not listed — confirm with the team
  • RU015
    Rostov-on-Don
    Site status: Not listed — confirm with the team
  • RU004
    Saint Petersburg
    Site status: Not listed — confirm with the team
  • RU005
    Saint Petersburg
    Site status: Not listed — confirm with the team
  • RU013
    Saint Petersburg
    Site status: Not listed — confirm with the team
  • RU002
    Saratov
    Site status: Not listed — confirm with the team
Serbia · 4 sites
  • RS001
    Belgrade
    Site status: Not listed — confirm with the team
  • RS003
    Belgrade
    Site status: Not listed — confirm with the team
  • RS002
    Kragujevac
    Site status: Not listed — confirm with the team
  • RS004
    Novi Kneževac
    Site status: Not listed — confirm with the team
Slovakia · 1 site
  • SK001
    Liptovský Mikuláš
    Site status: Not listed — confirm with the team
Ukraine · 8 sites
  • UA012
    Dnipropetrovsk
    Site status: Not listed — confirm with the team
  • UA004
    Geikivka
    Site status: Not listed — confirm with the team
  • UA007
    Hlevakha
    Site status: Not listed — confirm with the team
  • UA005
    Kherson
    Site status: Not listed — confirm with the team
  • UA008
    Kyiv
    Site status: Not listed — confirm with the team
  • UA009
    Lviv
    Site status: Not listed — confirm with the team
  • UA002
    Smila
    Site status: Not listed — confirm with the team
  • UA003
    Vinnytsia
    Site status: Not listed — confirm with the team
United States · 17 sites
  • US010
    Anaheim, California
    Site status: Not listed — confirm with the team
  • US020
    Cerritos, California
    Site status: Not listed — confirm with the team
  • US009
    Escondido, California
    Site status: Not listed — confirm with the team
  • US022
    Garden Grove, California
    Site status: Not listed — confirm with the team
  • US018
    Long Beach, California
    Site status: Not listed — confirm with the team
  • US011
    San Diego, California
    Site status: Not listed — confirm with the team
  • US021
    Washington D.C., District of Columbia
    Site status: Not listed — confirm with the team
  • US004
    Kissimmee, Florida
    Site status: Not listed — confirm with the team
  • US015
    North Miami, Florida
    Site status: Not listed — confirm with the team
  • US019
    Lake Charles, Louisiana
    Site status: Not listed — confirm with the team
  • US016
    St Louis, Missouri
    Site status: Not listed — confirm with the team
  • US002
    Cedarhurst, New York
    Site status: Not listed — confirm with the team
  • US005
    Charleston, South Carolina
    Site status: Not listed — confirm with the team
  • US003
    Austin, Texas
    Site status: Not listed — confirm with the team
  • US012
    Austin, Texas
    Site status: Not listed — confirm with the team
  • US001
    Dallas, Texas
    Site status: Not listed — confirm with the team
  • US013
    Dallas, Texas
    Site status: Not listed — confirm with the team
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study involving Brexpiprazole. Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.

Who might this study be for?

This study may concern people with schizophrenia; age range: From 18 Years to 65 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by H. Lundbeck A/S, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me